Sign Out
Since early embryonic deaths and teratogenicity have been observed in animal studies for favipiravir, do not administer the drug to women known or suspected to be pregnant. (See "Contraindications" and "Use in Pregnancy & Lactation").
When administering favipiravir to women of child-bearing potential, confirm a negative pregnancy test result before starting the treatment. Explain fully the risks and instruct thoroughly to use most effective contraceptive methods with her partner during and for 7 days after the end of the treatment. (See "Use in Pregnancy & Lactation"). If pregnancy is suspected during the treatment, instruct to discontinue the treatment immediately and to consult a doctor.
Favipiravir is distributed in sperm. When administering the drug to male patients, explain fully the risks and instruct thoroughly to use most effective contraceptive methods in sexual intercourse during and for 7 days after the end of the treatment (men must wear a condom). In addition, instruct not to have sexual intercourse with pregnant women. (See "Use in Pregnancy & Lactation" and "Pharmacology: Pharmacokinetics: Distribution under Actions").
Prior to the treatment, explain thoroughly the efficacy and risks (including the risk of exposure to fetus) to patients or their family members and written informed consent prior to administration of the drug shall be obtained by the prescriber. (See "Contraindications", "Precautions" and "Use in Pregnancy & Lactation").
Examine carefully the necessity of favipiravir before use.
